A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Clinical trial NCT06008288 · RECRUITING

Trial details

NCT number: NCT06008288
Sponsor: Allist Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

KRAS P.G12C Pancreatic Cancer Solid Tumor

Start date: 2023-10-27
Primary completion: 2026-12-31
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.